

CCDC144A (C-19): sc-246107

BACKGROUND

CCDC144A (coiled-coil domain containing 144A), also known as KIAA0565, FLJ43983, or MGC164650, is a 1,427 amino acid protein expressed as 3 isoforms produced by alternative splicing events. CCDC144A is encoded by a gene mapping to human chromosome 17p11.2. Chromosome 17 makes up over 2.5% of the human genome with about 81 million bases encoding over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes. Chromosome 17 is also linked to neurofibromatosis, a condition characterized by neural and epidermal lesions, and dysregulated Schwann cell growth. Alexander disease, Birt-Hogg-Dube syndrome and Canavan disease are also associated with chromosome 17.

REFERENCES

1. Welsch, M.J., et al. 2005. Birt-Hogg-Dube syndrome. *Int. J. Dermatol.* 44: 668-673.
2. Nusbaum, R., et al. 2006-2007. Susceptibility to breast cancer: hereditary syndromes and low penetrance genes. *Breast Dis.* 27: 21-50.
3. Al-Dirbashi, O.Y., et al. 2007. Quantification of N-acetylaspartic acid in urine by LC-MS/MS for the diagnosis of Canavan disease. *J. Inherit. Metab. Dis.* 30: 612.
4. Dann, R.B., et al. 2007. Strategies for ovarian cancer prevention. *Obstet. Gynecol. Clin. North Am.* 34: 667-686.
5. Farrell, C.J. and Plotkin, S.R. 2007. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. *Neurol. Clin.* 25: 925-946.
6. Suela, J., et al. 2007. Neurofibromatosis 1, and Not TP53, seems to be the main target of chromosome 17 deletions in *de novo* acute myeloid leukemia. *J. Clin. Oncol.* 25: 1151-1152.
7. Tai, Y.C., et al. 2007. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *J. Natl. Cancer Inst.* 99: 1811-1814.
8. Yan, J., et al. 2007. BLIMP1 regulates cell growth through repression of p53 transcription. *Proc. Natl. Acad. Sci. USA* 104: 1841-1846.
9. Murakami, N., et al. 2008. Novel deletion mutation in GFAP gene in an infantile form of Alexander disease. *Pediatr. Neurol.* 38: 50-52.

CHROMOSOMAL LOCATION

Genetic locus: CCDC144A (human) mapping to 17p11.2.

SOURCE

CCDC144A (C-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the C-terminus of CCDC144A of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-246107 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

CCDC144A (C-19) is recommended for detection of CCDC144A of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with CCDC144B or CCDC144NL.

Molecular Weight of CCDC144A isoforms: 165/134/81 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.